Activated T cells from umbilical cord blood armed with anti-CD3 × anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: A strategy for providing antitumor effects after cord blood transplants

Transfusion

Volumn 52, Issue 1, 2012, Pages 63-75

  Thakur, Archana ^a,b   Sorenson, Carly ^a,b   Norkina, Oxana ^a,b   Schalk, Dana ^a,b   Ratanatharathorn, Voravit ^a,b   Lum, Lawrence G ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; BISPECIFIC ANTIBODY; CD20 ANTIBODY; CD3 ANTIBODY; INTERLEUKIN 2;

ALLOIMMUNITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOKINE RELEASE; CYTOTOXICITY; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; SOLID TUMOR; STEM CELL EXPANSION; T LYMPHOCYTE ACTIVATION; UMBILICAL CORD BLOOD;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD20; ANTIGENS, CD3; CELL LINE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FETAL BLOOD; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; PHENOTYPE; T-LYMPHOCYTES;

EID: 84855340009     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03232.x     Document Type: Article

References (56)

1. Brunstein CG, Setubal DC, Wagner JE,. Expanding the role of umbilical cord blood transplantation. Br J Haematol 2007; 137: 20-35. (Pubitemid 46426403)
2. Brunstein CG, Baker KS, Wagner JE,. Umbilical cord blood transplantation for myeloid malignancies. Curr Opin Hematol 2007; 14: 162-9. (Pubitemid 46175101)
3. Hofmeister CC, Zhang J, Knight KL, Le P, Stiff PJ,. Ex vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche. Bone Marrow Transplant 2007; 39: 11-23. (Pubitemid 44921650)
4. Schoemans H, Theunissen K, Maertens J, Boogaerts M, Verfaillie C, Wagner J,. Adult umbilical cord blood transplantation: a comprehensive review. Bone Marrow Transplant 2006; 38: 83-93.
5. Cornetta K, Laughlin M, Carter S, Wall D, Weinthal J, Delaney C, Wagner J, Sweetman R, McCarthy P, Chao N,. Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT). Biol Blood Marrow Transplant 2005; 11: 149-60. (Pubitemid 40186212)
6. Komanduri KV, St John LS, de Lima M, McMannis J, Rosinski S, McNiece I, Bryan SG, Kaur I, Martin S, Wieder ED, Worth L, Cooper LJ, Petropoulos D, Molldrem JJ, Champlin RE, Shpall EJ,. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T cell skewing. Blood 2007; 110: 4543-51. (Pubitemid 351377822)
7. Majhail NS, Brunstein CG, Wagner JE,. Double umbilical cord blood transplantation. Curr Opin Immunol 2006; 18: 571-5. (Pubitemid 44311458)
8. Rocha V, Gluckman E,. Clinical use of umbilical cord blood hematopoietic stem cells. Biol Blood Marrow Transplant 2006; 12 (Suppl 1): 34-41. (Pubitemid 43034117)
9. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID,. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010; 16: 232-6.
10. Delaney C, Gutman JA, Appelbaum FR,. Cord blood transplantation for haematological malignancies: conditioning regimens, double cord transplant and infectious complications. Br J Haematol 2009; 147: 207-16.
11. Brunstein CG, Barker JN, Weisdorf DJ, Defor TE, Miller JS, Blazar BR, McGlave PB, Wagner JE,. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007; 110: 3064-70. (Pubitemid 350006962)
12. Macmillan ML, Weisdorf DJ, Brunstein CG, Cao Q, Defor TE, Verneris MR, Blazar BR, Wagner JE,. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood 2009; 113: 2410-5.
13. Davis CC, Marti LC, Sempowski GD, Jeyaraj DA, Szabolcs P,. Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation. Cancer Res 2010; 70: 5249-58.
14. Han P, Hodge G, Story C, Xu X,. Phenotypic analysis of functional T-lymphocyte subtypes and natural-killer-cells in human cord-blood-relevance to umbilical-cord blood transplantation. Br J Haematol 1995; 89: 733-40.
15. D'Arena G, Musto P, Cascavilla N, Di Giorgio G, Fusilli S, Zendoli F, Carotenuto M,. Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features. Haematologica 1998; 83: 197-203. (Pubitemid 28209124)
16. Szabolcs P, Park KD, Reese M, Marti L, Broadwater G, Kurtzberg J,. Coexistent naive phenotype and higher cycling rate of cord blood T cells as compared to adult peripheral blood. Exp Hematol 2003; 31: 708-14. (Pubitemid 36945384)
17. Hassan J, Reen DJ,. Human recent thymic emigrants-identification, expansion, and survival characteristics. J Immunol 2001; 167: 1970-6. (Pubitemid 32747502)
18. Soares MVD, Borthwick NJ, Maini MK, Janossy G, Salmon M, Akbar AN,. IL-7-dependent extrathymic expansion of CD45RA(+) T cells enables preservation of a naive repertoire. J Immunol 1998; 161: 5909-17. (Pubitemid 28535958)
19. Fukui T, Katamura K, Abe N, Kiyomasu T, Iio J, Ueno H, Mayumi M, Furusho K,. IL-7 induces proliferation, variable cytokine-producing ability and IL-2 responsiveness in naive CD4(+) T-cells from human cord blood. Immunol Lett 1997; 59: 21-8. (Pubitemid 27407679)
20. von Freeden-Jeffry U, Solvason N, Howard M, Murray R,. The earliest T lineage-committed cells depend on IL-7 for Bcl-2 expression and normal cell cycle progression. Immunity 1997; 7: 147-54. (Pubitemid 27357272)
21. Cookson S, Reen D,. IL-15 drives neonatal T cells to acquire CD56 and become activated effector cells. Blood 2003; 102: 2195-7. (Pubitemid 37122398)
22. Szabolcs P, Cairo MS,. Unrelated umbilical cord blood transplantation and immune reconstitution. Semin Hematol 2010; 47: 22-36.
23. Jin NR, Lum LG, Ratanatharathorn V, Sensenbrenner LL,. Anti-CD3-activated splenocytes enhance survial in lethally irradiated mice after transplant of syngeneic hematopoietic stem cells. Exp Hematol 1995; 23: 1331-6. (Pubitemid 26046522)
24. Hexner EO, Danet-Desnoyers GA, Zhang Y, Frank DM, Riley JL, Levine BL, Porter DL, June CH, Emerson SG,. Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation. Biol Blood Marrow Transplant 2007; 13: 1135-44. (Pubitemid 47413014)
25. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringdén O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM,. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-62. (Pubitemid 20069191)
26. Cairo MS, Wagner EL, Fraser J, Cohen G, van de Ven C, Carter SL, Kernan NA, Kurtzberg J,. Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a Cord Blood Transplantation (COBLT) Study report. Transfusion 2005; 45: 856-66. (Pubitemid 40798775)
27. Fraser JK, Cairo MS, Wagner EL, McCurdy PR, Baxter-Lowe LA, Carter SL,. Cord Blood Transplantation Study (COBLT): cord blood bank standard operating procedures. 7th ed. Philadelphia: W.B. Saunders Co.; 1998. p. 521-61.
28. Gall JM, Davol PA, Grabert RC, Deaver M, Lum LG,. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro. Exp Hematol 2005; 33: 452-9. (Pubitemid 40387628)
29. Sen M, Wankowski DM, Garlie NK, Siebenlist RE, Van Epps D, LeFever AV, Lum LG,. Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu tumors. J Hematother Stem Cell Res 2001; 10: 247-60. (Pubitemid 32423549)
30. Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, Davol PA, Lum LG,. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res 2006; 12: 569-76. (Pubitemid 43166151)
31. Spanholtz J, Tordoir M, Eissens D, Preijers F, van der Meer A, Joosten I, Schaap N, de Witte TM, Dolstra H,. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. Plos ONE 2010; 5: e9221.
32. Introna M, Pievani A, Borleri G, Capelli C, Algarotti A, Mico C, Grassi A, Oldani E, Golay J, Rambaldi A,. Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. Biol Blood Marrow Transplant 2010; 16: 1603-7.
33. Kobari L, Giarratana MC, Gluckman JC, Douay L, Rosenzwajg M,. Ex vivo expansion does not alter the capacity of umbilical cord blood CD34+ cells to generate functional T lymphocytes and dendritic cells. Stem Cells 2006; 24: 2150-7. (Pubitemid 44477140)
34. Gluckman E, Rocha V,. Cord blood transplantation: state of the art. Haematologica-Hematol J 2009; 94: 451-4.
35. Serrano LM, Pfeiffer T, Olivares S, Numbenjapon T, Bennitt J, Kim D, Smith D, McNamara G, Al-Kadhimi Z, Rosenthal J, Forman SJ, Jensen MC, Cooper LJ,. Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood 2006; 107: 2643-52.
36. Tammana S, Huang X, Wong M, Milone MC, Ma LN, Levine BL, June CH, Wagner JE, Blazar BR, Zhou X,. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther 2010; 21: 75-86.
37. Chalmers IMH, Janossy G, Contreras M, Navarette C,. Intracellular cytokine profile of cord and adult blood lymphocytes. Blood 1998; 92: 11-8. (Pubitemid 28303169)
38. Godfrey WR, Spoden DJ, Ge YG, Baker SR, Liu BL, Levine BL, June CH, Blazar BR, Porter SB,. Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood 2005; 105: 750-8. (Pubitemid 40070762)
39. Takahata Y, Nomura A, Takada H, Ohga S, Furuno K, Hikino S, Nakayama H, Sakaguchi S, Hara T,. CD25(+)CD4(+) T cells in human cord blood: an immunoregulatory subset with naive phenotype and specific expression of forkhead box p3 (Foxp3) gene. Exp Hematol 2004; 32: 622-9. (Pubitemid 38891531)
40. Ho VT, Soiffer RJ,. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001; 98: 3192-204.
41. Martin PJ, Hansen JA, Torok-Storb B, Durnam D, Przepiorka D, O'Quigley J, Sanders J, Sullivan KM, Witherspoon RP, Deeg HJ,. Graft failure in patients receiving T-cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 1988; 3: 445-56.
42. Tang Q, Grzywacz B, Wang HB, Kataria N, Cao Q, Wagner JE, Blazar BR, Miller JS, Verneris MR,. Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional. J Immunol 2008; 181: 4507-15.
43. Kaminski BA, Kadereit S, Miller RE, Leahy P, Stein KR, Topa DA, Radivoyevitch T, Veigl ML, Laughlin MJ,. Reduced expression of NFAT-associated genes in UCB versus adult CD4(+) T lymphocytes during primary stimulation. Blood 2003; 102: 4608-17. (Pubitemid 37494131)
44. Krampera M, Tavecchia L, Benedetti F, Nadali G, Pizzolo G,. Intracellular cytokine profile of cord blood T-, and NK- cells and monocytes. Haematologica 2000; 85: 675-9. (Pubitemid 30617100)
45. Chipeta J, Komada Y, Zhang XL, Sakurai M, Azuma E,. Intracellular cytokine profiles of cord and adult blood lymphocytes. Blood 1999; 93: 1120-1.
46. Niederwieser D, Herold M, Woloszczuk W, Aulitzky W, Meister B, Tilg H, Gastl G, Bowden R, Huber C,. Endogenous IFN-gamma during human bone-marrow transplantation-analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation 1990; 50: 620-5. (Pubitemid 20358535)
47. Ferrara JLM, Deeg HJ,. Graft-versus-host disease. N Engl J Med 1991; 324: 667-74.
48. Dickinson AM, Sviland L, Hamilton PJ, Usher P, Taylor P, Jackson G, Dunn J, Proctor SJ,. Cytokine involvement in predicting clinical graft-versus-host disease in allogeneic bone-marrow transplant recipients. Bone Marrow Transplant 1994; 13: 65-70. (Pubitemid 24052268)
49. Holler E, Kolb HJ, Hintermeierknabe R, Mittermuller J, Thierfelder S, Kaul M, Wilmanns W,. Role of tumor-necrosis-factor-alpha in acute graft-versus-host disease and complications following allogeneic bone-marrow transplantation. Transplant Proc 1993; 25: 1234-6. (Pubitemid 23078969)
50. Suen Y, Lee SM, Qian J, van de Ven C, Cairo MS,. Dysregulation of lymphokine production in the neonate and its impact on neonatal cell mediated immunity. Vaccine 1998; 16: 1369-77. (Pubitemid 28364670)
51. Boise LH, Petryniak B, Mao XH, June CH, Wang CY, Lindsten T, Bravo R, Kovary K, Leiden JM, Thompson CB,. The NFAT-1 DNA-binding complex in activated T-cells contains Fra-1 and JunB. Mol Cell Biol 1993; 13: 1911-9. (Pubitemid 23068131)
52. Yang Y, Ochando JC, Bromberg JS, Ding YZ,. Of a distant T-bet enhancer responsive to IL-12/Stat4 and IFN gamma/Stat1 signals. Blood 2007; 110: 2494-500. (Pubitemid 47523171)
53. Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, Glimcher LH,. Distinct effects of T-bet in T(H)1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science 2002; 295: 338-42. (Pubitemid 34074366)
54. Lum LG, Rathore R, Dizon D, Wang D, Al-Kadhimi Z, Uberti JP, Ratanatharathorn V,. Induction of immune responses and improved survival after infusions of T cells armed with anti-CD3 X anti-Her2/neu bispecific antibody in stage IV breast cancer patients (phase I). ASH Annu Meet Abstr 2007; 110: 2747.
55. Lum LG, Rathore R, Dizon D, Wang D, Al-Kadhimi Z, Uberti JP, Skuba C, Steele P, Sandborg R, Ratanatharathorn V,. Phase I trial of multiple infusions of autologous activated T cells with anti-CD3 x anti-CD20 bispecific antibody (CD20Bi) after autologous peripheral blood stem cell transplant for non-Hodgkin's lymphoma to improve graft-vs-lymphoma effects. 110 ed. 2007.
56. Lum LG, Al-Kadhimi Z, Skuba C, Roger Williams Hospital BMT/Immunotherapy Team, Ratanatharathorn V, Uberti JP,. Enhanced anti-breast cancer cytotoxicity after autologous peripheral blood stem cell transplant (PBSCT) by boosting with multiple infusions of activated T cells (ATC) armed with anti-CD3 x anti-Her2 bispecific antibody (Her2Bi) prior to PBSCT. ASH Annu Meet Abstr 2007; 110: 2748.